These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 32782203)
1. Central Nervous System Post-transplant Lymphoproliferative Disorder: Response to Ibrutinib. Kallam A; Hansen N; Bierman P Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e930-e933. PubMed ID: 32782203 [No Abstract] [Full Text] [Related]
2. Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis. Lauer EM; Waterhouse M; Braig M; Mutter J; Bleul S; Duque-Afonso J; Duyster J; Marks R; Reinacher PC; Prinz M; Illerhaus G; Finke J; Schorb E; Scherer F Br J Haematol; 2020 Jul; 190(2):e110-e114. PubMed ID: 32452526 [No Abstract] [Full Text] [Related]
3. Successful treatment of systemic and central nervous system post-transplant lymphoproliferative disorder without the use of high-dose methotrexate or radiation. Mahapatra S; Chin CC; Iagaru A; Heerema-McKenney A; Twist CJ Pediatr Blood Cancer; 2014 Nov; 61(11):2107-9. PubMed ID: 25066638 [TBL] [Abstract][Full Text] [Related]
4. Successful Rapid Oral Desensitization to Ibrutinib in a Patient With Severe Immediate Hypersensitivity Reaction. Tsilimidos G; Horisberger A; Ribi C; Cairoli A; Stalder G Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):e745-e747. PubMed ID: 34158264 [No Abstract] [Full Text] [Related]
5. [Mantle cell lymphoma with central nervous system relapse successfully treated with nasogastric-tube administration of ibrutinib]. Okahashi N; Uchihara M; Hoshino E Rinsho Ketsueki; 2020; 61(10):1508-1510. PubMed ID: 33162449 [TBL] [Abstract][Full Text] [Related]
6. [Primary central nervous system post-transplant lymphoproliferative disorders]. Honda M; Koga M; Kanda T Brain Nerve; 2014 Aug; 66(8):947-54. PubMed ID: 25082316 [TBL] [Abstract][Full Text] [Related]
8. Susceptibility-weighted imaging and diffusion-weighted imaging findings in central nervous system monomorphic B cell post-transplant lymphoproliferative disorder before and after treatment and comparison with primary B cell central nervous system lymphoma. Ginat DT; Purakal A; Pytel P J Neurooncol; 2015 Nov; 125(2):297-305. PubMed ID: 26341369 [TBL] [Abstract][Full Text] [Related]
9. A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy. Carella M; Stefoni V; Broccoli A; Argnani L; Zinzani PL Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e817-e819. PubMed ID: 34281758 [No Abstract] [Full Text] [Related]
10. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use. Chen F; Pang D; Guo H; Ou Q; Wu X; Jiang X; Wei X; Liu S; Huang L; Liang Z; Zhou D; Li W Cancer Med; 2020 Nov; 9(22):8676-8684. PubMed ID: 33068336 [TBL] [Abstract][Full Text] [Related]
11. Ibrutinib in primary central nervous system diffuse large B-cell lymphoma. T Low J; B Peters K CNS Oncol; 2020 Mar; 9(1):CNS51. PubMed ID: 32141313 [TBL] [Abstract][Full Text] [Related]
13. Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder. Czyzewski K; Styczynski J; Krenska A; Debski R; Zajac-Spychala O; Wachowiak J; Wysocki M Leuk Lymphoma; 2013 Mar; 54(3):503-6. PubMed ID: 22873830 [TBL] [Abstract][Full Text] [Related]
14. EBV-positive post-transplant lymphoproliferative disorder presenting as primary diffuse large B-cell lymphoma of the central nervous system. Xu H; Rewerska J; Aardsma N; Slavin K; Valyi-Nagy T; Ni H Folia Neuropathol; 2017; 55(3):221-226. PubMed ID: 28984115 [TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation. Nozzoli C; Bartolozzi B; Guidi S; Orsi A; Vannucchi AM; Leoni F; Bosi A Leuk Lymphoma; 2006 Jan; 47(1):167-9. PubMed ID: 16321845 [TBL] [Abstract][Full Text] [Related]
16. B-cell prolymphocytic leukaemia with a t(4;14) FGFR3/IGH translocation: response to ibrutinib. George P; Brown A; Weinkove R Pathology; 2020 Jun; 52(4):491-492. PubMed ID: 32349864 [No Abstract] [Full Text] [Related]
17. [Combination of ibrutinib and temozolomide for the treatment of newly diagnosed elderly primary central nervous system diffuse large B cell lymphoma: a case report]. Wang L; Li X; He YZ Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):482. PubMed ID: 32654461 [No Abstract] [Full Text] [Related]
18. Complete Response of a Young Woman With MYD88 Pabon CM; Neff JL; Forns TE; Wang J Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e809-e812. PubMed ID: 32660904 [No Abstract] [Full Text] [Related]
19. CSF IgH gene rearrangement analysis in isolated post-transplant lymphoproliferative disorder of the central nervous system. Baehring JM; Landry ML; Cooper D; Hui P; Bannykh S J Neurooncol; 2008 Jan; 86(1):57-60. PubMed ID: 17909942 [TBL] [Abstract][Full Text] [Related]
20. EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases. Sanz J; Arango M; Senent L; Jarque I; Montesinos P; Sempere A; Lorenzo I; Martín G; Moscardó F; Mayordomo E; Salavert M; Cañigral C; Boluda B; Salazar C; López-Hontangas JL; Sanz MA; Sanz GF Bone Marrow Transplant; 2014 Mar; 49(3):397-402. PubMed ID: 24292521 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]